search
Back to results

Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study (Find-AF2)

Primary Purpose

Ischemic Stroke, Atrial Fibrillation

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
7-day Holter ECG
Implantable cardiac monitor
Standard of care
Sponsored by
University of Leipzig
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Ischemic Stroke focused on measuring Atrial Fibrillation, Ischemic Stroke, ECG Monitoring, Secondary Prevention

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Recent ischemic stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery) and/or a corresponding lesion on brain imaging within the last 30 days
  2. Age ≥ 60 years
  3. Patient without or with only slight disability (modified Rankin Scale score ≤ 2) before onset of stroke-related symptoms.
  4. Written informed consent

Exclusion Criteria:

  1. Known history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG
  2. Current indication or contraindication for oral anticoagulation at randomisation
  3. Intracerebral bleeding in medical history
  4. Patient scheduled for ECG-monitoring lasting > 7 days (Holter-ECG, implanted loop recorder, etc.)
  5. Implanted pacemaker device or cardioverter/ defibrillator
  6. Patient not willing to be treated with oral anticoagulants
  7. Carotid artery stenosis ipsilateral to the current ischemic stroke needing operation or intervention.
  8. History of carotid endarterectomy or percutaneous intervention of cerebral artery within the last 30 days.
  9. Life expectancy <1 year for reasons other than stroke (e.g. metastatic cancer)
  10. patients under legal supervision or guardianship
  11. psychological/mental or other inabilities to supply required information (e.g. fill out the questionnaire due to dementia, language difficulties,...) or participate in the required tests
  12. participation in other randomised interventional trials
  13. suspected lack of compliance

Sites / Locations

  • ISD MünchenRecruiting
  • Klinikum NürnbergRecruiting
  • University of Leipzig, Clinic for NeurologyRecruiting
  • Klinikum Altenburger LandRecruiting
  • Klinikum Aschaffenburg-AlzenauRecruiting
  • Universitätsklinikum AugsburgRecruiting
  • Rhön Klinikum Campus Bad NeustadtRecruiting
  • Sozialstiftung Bamberg; Klinikum am BruderwaldRecruiting
  • Vivantes Klinikum SpandauRecruiting
  • BG Klinikum, Unfall-KH Berlin gGmbHRecruiting
  • Vivantes Klinikum Neukölln BerlinRecruiting
  • Vivantes, Humboldt-Klinikum BerlinRecruiting
  • Evangelisches Klinikum Bethel, Klinik für NeurologieRecruiting
  • Universitätsklinikum BonnRecruiting
  • Klinikum Bremen MitteRecruiting
  • Klinikum Coburg, Medizinische Klinik für Innere Medizin und KardiologieRecruiting
  • Klinikum DarmstadtRecruiting
  • Städtisches Klinikum Dresden, Standort FriedrichstadtRecruiting
  • Universitätsklinikum Carl Gustav CarusRecruiting
  • Universitätsklinikum ErlangenRecruiting
  • University of Essen, Clinic for NeurologyRecruiting
  • Klinikum Frankfurt HöchstRecruiting
  • Universitätsklinikum FrankfurtRecruiting
  • Klinikum FuldaRecruiting
  • Universitätsklinikum Gießen und Marburg GmbHRecruiting
  • University of Göttingen, Clinic for NeurologyRecruiting
  • Bezirkskrankenhaus GünzburgRecruiting
  • Krankenhaus Martha-Maria Halle-DölauRecruiting
  • Albertinenkrankenhaus HamburgRecruiting
  • Asklepios Klinik Altona HamburgRecruiting
  • Asklepios Klinik Wandsbek, HamburgRecruiting
  • Universitätsklinikum Hamburg-EppendorfRecruiting
  • Medizinische Hochschule HannoverRecruiting
  • Universitätsklinikum HeidelbergRecruiting
  • Klinikum HöxterRecruiting
  • Klinikum IbbenbürenRecruiting
  • Westpfalz Klinikum GmbH - Standort Kaiserslautern
  • Klinikum St. Georg Leipzig
  • Städtisches Klinikum Lüneburg gemeinnützige GmbHRecruiting
  • University of Mainz, Clinic for NeurologyRecruiting
  • Universitätsklinikum Mannheim
  • Carl-von-Basedow Klinikum MerseburgRecruiting
  • Klinikum MindenRecruiting
  • Ökumenisches Hainich Klinikum MühlhausenRecruiting
  • Universitätsklinikum MünsterRecruiting
  • Klinikum Osnabrück GmbHRecruiting
  • Klinikum PassauRecruiting
  • Nordwest-Krankenhaus Sanderbusch, Klinik für NeurologieRecruiting
  • Kreisklinikum SiegenRecruiting
  • Kliniken Südostbayern AG, Klinikum TraunsteinRecruiting
  • Universitätsklinikum TübingenRecruiting
  • Universitätsklinikum UlmRecruiting
  • Helios Dr. Horst Schmidt-Kliniken WiesbadenRecruiting
  • Universitätsklinikum WürzburgRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Risk-adapted ECG monitoring for atrial fibrillation

Standard of Care

Arm Description

Intervention Group with high Risk for AF: Continuous Rhythm Monitoring using an implantable cardiac Monitor Intervention group with low risk for AF: 7-day Holter ECG at baseline, after 3 and 12 months and then annually until the end of the study or the first occurrence of atrial Fibrillation

Standard of care rhythm monitoring

Outcomes

Primary Outcome Measures

Primary efficacy endpoint: Time until recurrent ischemic stroke or systemic embolism
The trial will be event driven. The minimum follow-up in each patient is 24 months, but may be followed for up to 60 months.
Primary safety endpoint: Time until the first haemorrhagic stroke
Time until the first haemorrhagic stroke

Secondary Outcome Measures

Time until the combination of stroke, myocardial infarction and cardiovascular death
Time until the combination of stroke, myocardial infarction and cardiovascular death
Time until any stroke
Time until any stroke
Time until new onset of AF
Time until new onset of Atrial Fibrillation
Time until all cause mortality
Time until all cause mortality
Time until myocardial infarction
Time until myocardial infarction
Changes in quality of life (QoL), measured by the stroke impact scale (SIS-16)
Changes in quality of life (QoL), measured by the stroke impact scale (SIS-16). The SIS-16 ranges from 16 to 80, with higher scores showing better Quality of life.
Changes in the EQ-5D five dimensional Quality of Life (QoL)
Changes in the EQ-5D five dimensional Quality of Life (QoL)
Changes in the overall QoL visual analog scale
Changes in the overall QoL visual analog scale

Full Information

First Posted
April 24, 2020
Last Updated
January 26, 2023
Sponsor
University of Leipzig
Collaborators
Johannes Gutenberg University Mainz
search

1. Study Identification

Unique Protocol Identification Number
NCT04371055
Brief Title
Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study
Acronym
Find-AF2
Official Title
Intensive Heart Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 7, 2020 (Actual)
Primary Completion Date
June 30, 2026 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Leipzig
Collaborators
Johannes Gutenberg University Mainz

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients who have suffered a stroke are having an increased risk of having recurrent stroke in the future. This risk of stroke is increased by atrial fibrillation, which often "comes and goes" (called paroxysmal) and hence escapes routine diagnostics. The hypothesis of Find-AF 2 is that enhanced (evaluation in a ECG core lab), prolonged (at least 7 days of rhythm monitoring annually) and intensified (continuous rhythm monitoring in high risk patients) not only finds atrial fibrillation more often, but that changes in therapeutic management (e. g. start of anticoagulation after detection of atrial fibrillation) results in a decrease of cardioembolism (which can be either recurrent stroke or systemic embolism). To prove this hypothesis, patients will be randomised into two groups: the first group will receive the currently available standard care for patients with stroke. In the second group, cardiac rhythm monitoring adapted to the risk of the occurrence of atrial fibrillation is performed - either with a 7-day long-term ECG (at baseline, after 3 and 12 months and every 12 months thereafter) or with continuous monitoring using an implantable cardiac monitor. If atrial fibrillation is detected, this information will be given to the treating study physician. Any therapeutic decision is at the discretion of the treating physician, but should follow current guidelines.
Detailed Description
The Find AF 2 study will investigate whether intensified rhythm monitoring in patients with recent ischemic stroke leads to a decrease in recurrent thromboembolism (defined as recurrent ischemic stroke or systemic embolism). This will be achieved by identifying patients with paroxysmal atrial fibrillation and subsequently switching secondary prevention therapy from antiplatelet therapy to oral anticoagulation. The intensity of heart rhythm monitoring will be risk-adjusted: Patients with an estimated low risk of atrial fibrillation receive a 7-day Holter ECG, which is repeated after 3 and 12 months and annually thereafter. Patients with a high risk of atrial fibrillation (defined by increased supraventricular ectopic activity) receive continuous ECG monitoring using an implanted loop recorder. The control arm is treated according to local standards, which includes cardiac rhythm monitoring for at least 24 hours according to current guidelines. Prior to randomization, a 24-hour Holter ECG is performed in both study arms, ensuring minimal ECG monitoring for patients in the control arm and allowing risk stratification in the intervention arm. Additional ECG monitoring using stroke telemetry and/or additional Holter ECGs is possible according to local standards, provided it does not exceed 7 days. Patients in both study arms will be followed up for at least 24 months. It should be noted that this study only provides diagnostic information, the therapeutic decision is left to the treating physician.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Stroke, Atrial Fibrillation
Keywords
Atrial Fibrillation, Ischemic Stroke, ECG Monitoring, Secondary Prevention

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomised, parallel, multicenter interventional trial with blinded assessment of the primary endpoint
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
5200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Risk-adapted ECG monitoring for atrial fibrillation
Arm Type
Experimental
Arm Description
Intervention Group with high Risk for AF: Continuous Rhythm Monitoring using an implantable cardiac Monitor Intervention group with low risk for AF: 7-day Holter ECG at baseline, after 3 and 12 months and then annually until the end of the study or the first occurrence of atrial Fibrillation
Arm Title
Standard of Care
Arm Type
Other
Arm Description
Standard of care rhythm monitoring
Intervention Type
Other
Intervention Name(s)
7-day Holter ECG
Intervention Description
7-day Holter ECG at baseline and after 3 and 12 months and then annually until the end of the study or the first (in patients with low risk of atrial fibrillation)
Intervention Type
Other
Intervention Name(s)
Implantable cardiac monitor
Intervention Description
Continuous rhythm monitoring using an implantable cardiac monitor
Intervention Type
Other
Intervention Name(s)
Standard of care
Intervention Description
Usual care according to current guidelines (in patients with low and high risk of atrial fibrillation)
Primary Outcome Measure Information:
Title
Primary efficacy endpoint: Time until recurrent ischemic stroke or systemic embolism
Description
The trial will be event driven. The minimum follow-up in each patient is 24 months, but may be followed for up to 60 months.
Time Frame
from the date of randomization until the date of first documented ischemic stroke or date of first systemic embolism, whichever comes first, assessed up to 60 months
Title
Primary safety endpoint: Time until the first haemorrhagic stroke
Description
Time until the first haemorrhagic stroke
Time Frame
from the date of randomization until the date of first documented haemorrhagic stroke, assessed up to 60 months
Secondary Outcome Measure Information:
Title
Time until the combination of stroke, myocardial infarction and cardiovascular death
Description
Time until the combination of stroke, myocardial infarction and cardiovascular death
Time Frame
from the date of randomization until the date of first documented stroke, the date of myocardial infarction and the date of cardiovascular death, whichever comes first, assessed up to 60 months
Title
Time until any stroke
Description
Time until any stroke
Time Frame
from the date of randomization until the date of first documented any stroke, assessed up to 60 months
Title
Time until new onset of AF
Description
Time until new onset of Atrial Fibrillation
Time Frame
from the date of randomization until the date of first documented AF, assessed up to 60 months
Title
Time until all cause mortality
Description
Time until all cause mortality
Time Frame
from the date of randomization until the date of all cause mortality assessed up to 60 months
Title
Time until myocardial infarction
Description
Time until myocardial infarction
Time Frame
from the date of randomization until the date of all myocardial infarction, assessed up to 60 months
Title
Changes in quality of life (QoL), measured by the stroke impact scale (SIS-16)
Description
Changes in quality of life (QoL), measured by the stroke impact scale (SIS-16). The SIS-16 ranges from 16 to 80, with higher scores showing better Quality of life.
Time Frame
Mean change from baseline until study end assessed up to 60 months in both study arms
Title
Changes in the EQ-5D five dimensional Quality of Life (QoL)
Description
Changes in the EQ-5D five dimensional Quality of Life (QoL)
Time Frame
Mean change from baseline until study end assessed up to 60 months in both study arms
Title
Changes in the overall QoL visual analog scale
Description
Changes in the overall QoL visual analog scale
Time Frame
Mean change from baseline until study end assessed up to 60 months in both study arms, ranging from 0 to 100, with higher values indicating better quality of life

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Recent ischemic stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery) and/or a corresponding lesion on brain imaging within the last 30 days Age ≥ 60 years Patient without or with only slight disability (modified Rankin Scale score ≤ 2) before onset of stroke-related symptoms. Written informed consent Exclusion Criteria: Known history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG Current indication or contraindication for oral anticoagulation at randomisation Intracerebral bleeding in medical history Patient scheduled for ECG-monitoring lasting > 7 days (Holter-ECG, implanted loop recorder, etc.) Implanted pacemaker device or cardioverter/ defibrillator Patient not willing to be treated with oral anticoagulants Carotid artery stenosis ipsilateral to the current ischemic stroke needing operation or intervention. History of carotid endarterectomy or percutaneous intervention of cerebral artery within the last 30 days. Life expectancy <1 year for reasons other than stroke (e.g. metastatic cancer) patients under legal supervision or guardianship psychological/mental or other inabilities to supply required information (e.g. fill out the questionnaire due to dementia, language difficulties,...) or participate in the required tests participation in other randomised interventional trials suspected lack of compliance
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rolf Wachter, Prof. Dr.
Phone
+49-341-97-12650
Email
rolf.wachter@medizin.uni-leipzig.de
First Name & Middle Initial & Last Name or Official Title & Degree
Katrin Wasser, PD Dr. med.
Phone
+49-551-3920-194
Email
k.wasser@med.uni-goettingen.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rolf Wachter, Prof. Dr.
Organizational Affiliation
University of Leipzig, Clinic and Policlinis for Cardiology
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Klaus Gröschel, Prof. Dr.
Organizational Affiliation
University of Mainz, Clinic and Policlinis for Neurology
Official's Role
Principal Investigator
Facility Information:
Facility Name
ISD München
City
München
State/Province
Bayern
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Dichgans, Prof. Dr.
Facility Name
Klinikum Nürnberg
City
Nürnberg
State/Province
Bayern
ZIP/Postal Code
90471
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Nückel, MD
Phone
+49-911-398-2491
Email
martin.nueckel@klinikum-nuernberg.de
Facility Name
University of Leipzig, Clinic for Neurology
City
Leipzig
State/Province
Saxony
ZIP/Postal Code
04103
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dominik Michalski, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Rolf Wachter, Prof. Dr.
Facility Name
Klinikum Altenburger Land
City
Altenburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jörg Berrouschot, Prof. Dr.
Facility Name
Klinikum Aschaffenburg-Alzenau
City
Aschaffenburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oliver Bähr, Prof. Dr.
Facility Name
Universitätsklinikum Augsburg
City
Augsburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Ertl, PD Dr.
Facility Name
Rhön Klinikum Campus Bad Neustadt
City
Bad Neustadt An Der Saale
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hassan Soda, Dr.
Facility Name
Sozialstiftung Bamberg; Klinikum am Bruderwald
City
Bamberg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Herwig Strik, Prof. Dr.
Facility Name
Vivantes Klinikum Spandau
City
Berlin-Spandau
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jörg Müller, Prof. Dr.
Facility Name
BG Klinikum, Unfall-KH Berlin gGmbH
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mirko Seidel, Dr.
Facility Name
Vivantes Klinikum Neukölln Berlin
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Darius G Nabavi, Prof. Dr.
Facility Name
Vivantes, Humboldt-Klinikum Berlin
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bettina Schmitz, Prof. Dr.
Facility Name
Evangelisches Klinikum Bethel, Klinik für Neurologie
City
Bielefeld
ZIP/Postal Code
33611
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wolf R Schäbitz, Prof. Dr.
Facility Name
Universitätsklinikum Bonn
City
Bonn
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gabor Petzold, Prof. Dr.
Facility Name
Klinikum Bremen Mitte
City
Bremen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Kastrup, Prof. Dr.
Facility Name
Klinikum Coburg, Medizinische Klinik für Innere Medizin und Kardiologie
City
Coburg
ZIP/Postal Code
96450
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Mahnkopf, Dr.
Facility Name
Klinikum Darmstadt
City
Darmstadt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rainer Kollmar, Prof. Dr.
Facility Name
Städtisches Klinikum Dresden, Standort Friedrichstadt
City
Dresden
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sebastian Schellong, Prof. Dr.
Facility Name
Universitätsklinikum Carl Gustav Carus
City
Dresden
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lars P Pallesen, Dr.
Facility Name
Universitätsklinikum Erlangen
City
Erlangen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernd Kallmünzer, PD Dr.
Facility Name
University of Essen, Clinic for Neurology
City
Essen
ZIP/Postal Code
45147
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Köhrmann, Prof. Dr.
Facility Name
Klinikum Frankfurt Höchst
City
Frankfurt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thorsten Steiner, Prof. Dr.
Facility Name
Universitätsklinikum Frankfurt
City
Frankfurt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Natalia Kurka, Dr.
Facility Name
Klinikum Fulda
City
Fulda
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tobias Neumann-Haefelin, Prof. Dr.
Facility Name
Universitätsklinikum Gießen und Marburg GmbH
City
Gießen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Jünemann, Dr.
First Name & Middle Initial & Last Name & Degree
Hagen Huttner, Prof. Dr.
Facility Name
University of Göttingen, Clinic for Neurology
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jan Liman, Prof. Dr.
Facility Name
Bezirkskrankenhaus Günzburg
City
Günzburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gerhard F Hamann, Prof.
Facility Name
Krankenhaus Martha-Maria Halle-Dölau
City
Halle
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frank Hoffmann, Dr.
Facility Name
Albertinenkrankenhaus Hamburg
City
Hamburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Rosenkranz, PD Dr.
Facility Name
Asklepios Klinik Altona Hamburg
City
Hamburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joachim Röther, Prof. Dr.
Facility Name
Asklepios Klinik Wandsbek, Hamburg
City
Hamburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lars Marquardt, PD Dr. Dr.
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Götz Thomalla, Prof. Dr.
Facility Name
Medizinische Hochschule Hannover
City
Hannover
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karin Weißenborn, Prof. Dr.
Facility Name
Universitätsklinikum Heidelberg
City
Heidelberg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter A. Ringleb, Prof. Dr.
Facility Name
Klinikum Höxter
City
Höxter
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mark Obermann, Prof. Dr.
Facility Name
Klinikum Ibbenbüren
City
Ibbenbüren
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florian Bethke, Dr.
Facility Name
Westpfalz Klinikum GmbH - Standort Kaiserslautern
City
Kaiserslautern
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Klinikum St. Georg Leipzig
City
Leipzig
Country
Germany
Individual Site Status
Terminated
Facility Name
Städtisches Klinikum Lüneburg gemeinnützige GmbH
City
Lüneburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Waltraud Pfeilschifter, Prof. Dr.
Facility Name
University of Mainz, Clinic for Neurology
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Klaus Gröschel, Prof. Dr.
Facility Name
Universitätsklinikum Mannheim
City
Mannheim
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Carl-von-Basedow Klinikum Merseburg
City
Merseburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carsten Hobohm, Dr.
Facility Name
Klinikum Minden
City
Minden
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Schellinger, Prof. Dr.
Facility Name
Ökumenisches Hainich Klinikum Mühlhausen
City
Mühlhausen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marek Jauß, Prof. Dr.
Facility Name
Universitätsklinikum Münster
City
Münster
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jens Minnerup, Prof. Dr.
Facility Name
Klinikum Osnabrück GmbH
City
Osnabrück
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lars U Krause, Dr.
Facility Name
Klinikum Passau
City
Passau
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tobias Freilinger, Prof. Dr.
Facility Name
Nordwest-Krankenhaus Sanderbusch, Klinik für Neurologie
City
Sande
ZIP/Postal Code
26452
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pawel Kermer, Prof. Dr.
Facility Name
Kreisklinikum Siegen
City
Siegen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Grond, Prof. Dr.
Facility Name
Kliniken Südostbayern AG, Klinikum Traunstein
City
Traunstein
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thorleif Etgen, Prof. Dr.
Facility Name
Universitätsklinikum Tübingen
City
Tübingen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sven Poli, PD Dr.
Facility Name
Universitätsklinikum Ulm
City
Ulm
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katharina Althaus, Dr.
Facility Name
Helios Dr. Horst Schmidt-Kliniken Wiesbaden
City
Wiesbaden
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frank A Wollenweber, Prof. Dr.
Facility Name
Universitätsklinikum Würzburg
City
Würzburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karl G Häusler, Prof. Dr.

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Time Frame
after publication of the major results
Links:
URL
http://www.find-af2.com
Description
Study homepage with information for medical experts and the general public

Learn more about this trial

Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study

We'll reach out to this number within 24 hrs